Iovance Biotherapeutics is trading 4.19% higher at $14.80, with biotech-sector strength offering a possible tailwind. - No verified company announcement dated October 20 clearly explains the move. Recent reporting describes ESMO clinical data but does not link it to today’s share gain. - Biotech ETF XBI is up 2.10%; the broader market is also higher, with more modest gains. - No trading-volume context is available in the provided price data.